1. Home
  2. HSIC vs BIO Comparison

HSIC vs BIO Comparison

Compare HSIC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSIC
  • BIO
  • Stock Information
  • Founded
  • HSIC 1932
  • BIO 1952
  • Country
  • HSIC United States
  • BIO United States
  • Employees
  • HSIC N/A
  • BIO N/A
  • Industry
  • HSIC Medical Specialities
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • HSIC Health Care
  • BIO Industrials
  • Exchange
  • HSIC Nasdaq
  • BIO Nasdaq
  • Market Cap
  • HSIC 8.9B
  • BIO 8.7B
  • IPO Year
  • HSIC 1995
  • BIO N/A
  • Fundamental
  • Price
  • HSIC $73.13
  • BIO $346.64
  • Analyst Decision
  • HSIC Buy
  • BIO Buy
  • Analyst Count
  • HSIC 10
  • BIO 4
  • Target Price
  • HSIC $77.10
  • BIO $369.00
  • AVG Volume (30 Days)
  • HSIC 1.9M
  • BIO 209.1K
  • Earning Date
  • HSIC 11-11-2024
  • BIO 10-24-2024
  • Dividend Yield
  • HSIC N/A
  • BIO N/A
  • EPS Growth
  • HSIC N/A
  • BIO N/A
  • EPS
  • HSIC 2.70
  • BIO N/A
  • Revenue
  • HSIC $12,487,000,000.00
  • BIO $2,562,604,000.00
  • Revenue This Year
  • HSIC $6.71
  • BIO N/A
  • Revenue Next Year
  • HSIC $4.52
  • BIO $4.49
  • P/E Ratio
  • HSIC $26.45
  • BIO N/A
  • Revenue Growth
  • HSIC N/A
  • BIO N/A
  • 52 Week Low
  • HSIC $60.01
  • BIO $261.59
  • 52 Week High
  • HSIC $82.63
  • BIO $370.57
  • Technical
  • Relative Strength Index (RSI)
  • HSIC 63.03
  • BIO 66.40
  • Support Level
  • HSIC $65.32
  • BIO $311.04
  • Resistance Level
  • HSIC $70.50
  • BIO $337.50
  • Average True Range (ATR)
  • HSIC 1.74
  • BIO 8.57
  • MACD
  • HSIC 0.36
  • BIO 1.31
  • Stochastic Oscillator
  • HSIC 93.64
  • BIO 100.00

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: